Patient Voice Initiative

Patient Voice Initiative – Engaging patients in health care decision making

The Patient Voice Initiative began in 2015 when a group of stakeholders from industry, academia and patient groups came together to discuss methodologies and approaches for eliciting the patient perspective on the value of medicines.  As a result of these meetings a conference was organised aimed at increasing patient engagement in health technology assessment (HTA) in Australia.  Following the conference, a steering committee was formed to action items generated from the workshops.

The current steering committee membership is:

  • Kate Vines, Rare Cancers Australia
  • Richard Vines, Rare Cancers Australia
  • Jessica Bean, patient advocate
  • Simon Fifer, CaPPRe
  • Laurie Axford, CaPPRe
  • Todd Stephenson, Janssen Australia and New Zealand
  • Nathan Walters, Janssen Australia and New Zealand
  • Carlene Todd, Roche Australia
  • Zarli French, MSD Australia

All the information and ideas generated from any Patient Voice Initiative meeting is available and accessible to all those who participated. 

The Patient Voice Initiative events in September and October 2016 have been sponsored by:  Amgen, Bayer, BMS, CaPPRe, Janssen, MSD, Novartis, Pfizer, Roche.

If you would like to be involved in the Patient Voice Initiative moving forward please click on the link to register interest: Register

Download a copy of HTA for consumers from our recent Brisbane and Melbourne meetings here.

Summary notes from each of the workshops here:

Brisbane notes

Melbourne notes

Canberra notes

Outcomes from our Sydney forum in February 2016

Three broad areas of overall agreement emerged from the patient conference.